Telephone depression care management for Latino Medicaid health plan members: a pilot randomized controlled trial.

The objective of this pilot study was to provide a preliminary test of feasibility, acceptability, and efficacy of telephone depression care management among Latino Medicaid health plan members. Thirty-eight depressed primary care patients were enrolled in a pilot randomized trial of telephone depression care management + treatment as usual (TAU) versus TAU only. Bilingual care managers conducted care management for 3 months following an antidepressant prescription.

Barriers and facilitators of treatment for depression in a latino community: a focus group study.

We conducted focus groups with Latinos enrolled in a Medicaid health plan in order to ask about the barriers to and facilitators of depression treatment in general as well as barriers to participation in depression telephone care management. Telephone care management has been designed for and tested in primary care settings as a way of assisting physicians with caring for their depressed patients. It consists of regular brief contacts between the care manager and the patient; the care manager educates, tracks, and monitors patients with depression, coordinates care between the patient and primary care physician, and may provide short-term psychotherapy.

Adapted behavior therapy for persistently depressed primary care patients: an open trial.

Major depressive disorder is commonly treated in primary care settings. Psychotherapy occurring in primary care should take advantage of the unique aspects of the setting and must adapt to the problems and limitations of the setting. In this open trial, the authors used a treatment development model to adapt behavior therapy for primary care patients (n = 12) with persistent symptoms of depression, despite antidepressant medication treatment.

Open-label tiagabine monotherapy for major depressive disorder with anxiety.

Objective: Gamma-aminobutyric acid (GABA) plays a key role in the pathophysiology and treatment of depression and anxiety. Tiagabine, a selective GABA reuptake inhibitor (SGRI) that enhances normal GABA tone, was evaluated for its efficacy and safety in the treatment of depression comorbid with significant anxiety.

Method: In this 8-week, single-center, open-label study, adults with DSM-IV-diagnosed major depressive disorder and significant anxiety (i.